NCT06912035 is a Phase 2, PHASE3 clinical trial of Diacerein 50 mg Capsule in Uncontrolled Diabetes, sponsored by Universitas Sriwijaya.

Who is sponsoring NCT06912035?

NCT06912035 is sponsored by Universitas Sriwijaya.

What drugs are being tested in NCT06912035?

Interventions in NCT06912035: Diacerein 50 mg Capsule, Placebo.

What condition does NCT06912035 study?

NCT06912035 studies Uncontrolled Diabetes, Diabetes Mellitus Type 2.

Is NCT06912035 still recruiting?

NCT06912035 is currently completed. Last updated 4 April 2025.

Last reviewed 2025-04-04 · How we verify

NCT06912035

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Diacerein Supplementation on Interleukin-1β, Hs-CRP, TNF-α Levels and Glycemic Control in Uncontrolled Type 2 Diabetes Mellitus Patients at Dr. Mohammad Hoesin General Hospital Palembang

Completed Phase 2, PHASE3 Last updated 4 April 2025

What this trial tests

Phase 2, PHASE3 trial testing Diacerein 50 mg Capsule in Uncontrolled Diabetes in 34 participants. Completed in 8 November 2024.

Timeline

21 June 2024

Primary endpoint
8 November 2024

8 November 2024

Quick facts

Lead sponsor	Universitas Sriwijaya
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	34
Start date	21 June 2024
Primary completion	8 November 2024
Estimated completion	8 November 2024
Sites	1 location across Indonesia

Drugs / interventions tested

Diacerein 50 mg Capsule — full drug profile →
Placebo

Conditions studied

Uncontrolled Diabetes — all drugs for Uncontrolled Diabetes →
Diabetes Mellitus Type 2 — all drugs for Diabetes Mellitus Type 2 →

Sponsor

Universitas Sriwijaya — full company profile →

Who can join

Adults 60 to 60, any sex, with Uncontrolled Diabetes or Diabetes Mellitus Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if diacerein supplementation can help improve inflammation and glycemic control in adults with uncontrolled type 2 diabetes. It will also study the safety and tolerability of diacerein. The main questions it aims to answer are: * Does diacerein lower levels of inflammatory markers like interleukin-1β, hs-CRP, and TNF-α? * Does diacerein improve blood sugar control? * What side effects or problems do participants have when taking diacerein? Researchers will compare diacerein to a placebo (a look-alike substance with no active drug) to see if it works better for managing type 2 diabetes. Participants will: * Be adults aged 40-60 with uncontrolled type 2 diabetes * Take either diacerein or a placebo every day for 12 weeks * Visit the clinic for blood tests and monitoring at the beginning and end of the trial * Be evaluated for side effects and medication adherence\]

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in Drug Delivery Science for Diacerein: Strategies to Enhance Solubility, Bioavailability, and Pharmacokinetic Performance.
Naseri M, Ghobakhlou S, Heidarizade N, Akbari ME, et al · · 2025 · PMID 41471053 · DOI 10.3390/pharmaceutics17121539

Verify or expand the search:

Other trials of Diacerein 50 mg Capsule

Trials testing the same drug.

NCT07199933 — Diacerein in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease · NA · not yet recruiting
NCT06308068 — Bioequivalence Study of Diacerein 50 mg Capsule in Healthy Thai Volunteers · Phase 1 · unknown

Other recruiting trials for Uncontrolled Diabetes

Currently open trials in the same condition.

NCT06926855 — Community Health Workers Reduce Social Barriers That Affect the Health of Patients With High Blood Pressure and Diabetes · NA · active not recruiting

Other Universitas Sriwijaya trials

Trials by the same sponsor.

NCT07337863 — A Phase II/III Randomized Double-Blind Multicenter Study Comparing UC-MSC-Derived Secretome and Sodium Hyaluronate in Pa · Phase 2, PHASE3 · not yet recruiting
NCT07089329 — Efficacy of Striatin in Malnourished Children · Phase 3 · recruiting
NCT07586579 — Aerobic Exercise and Body Composition in Overweight and Obese Boys. · NA · completed
NCT07071220 — Efficacy of Vitamin C Supplementation on Serum IL-6 Levels and Disease Activity in Systemic Lupus Erythematosus Patients · NA · completed
NCT07083622 — Efficacy of Vitamin C Supplementation on Malondialdehid Levels and Disease Activity in SLE Patients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06912035 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitas Sriwijaya
Last refreshed: 4 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06912035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing